Costs and cost-efficacy analysis of the 2016 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults

Thumbnail
View/Open
Issue date
2017
Author
Rivero, Antonio
Pérez-Molina, José Antonio
Blasco, Antonio Javier
Arribas, José Ramón
Crespo, Manuel
Domingo, Pere
Estrada, Vicente
Iribarren, José Antonio
Knobel, Hernando
Lázaro, Pablo
López Aldeguer, José
Lozano, Fernando
Moreno, Santiago
Palacios, Rosario
Pineda, Juan Antonio
Pulido, Federico
Rubio, Rafael
de la Torre, Javier
Tuset, Montserrat
Gatell, Josep M.
Suggested citation
Rivero, Antonio; Pérez-Molina, José Antonio; Blasco, Antonio Javier; Arribas, José Ramón; Crespo, Manuel; Domingo, Pere; ... Gatell, Josep M.. (2017) . Costs and cost-efficacy analysis of the 2016 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults. Enfermedades Infecciosas y Microbiología Clínica, 2017, vol. 35, núm. 2, p. 88-99. https://doi.org/10.1016/j.eimc.2016.06.013.
Impact

Google Scholar logo  Google Scholar
Share
Export to Mendeley
Metadata
Show full item record
Abstract
Introduction: GESIDA and the AIDS National Plan panel of experts suggest preferred (PR), alternative (AR) and other regimens (OR) for antiretroviral treatment (ART) as initial therapy in HIV-infected patients for 2016. The objective of this study is to evaluate the costs and the efficiency of initiating treatment with these regimens. Methods: Economic assessment of costs and efficiency (cost/efficacy) based on decision tree analyses. Efficacy was defined as the probability of reporting a viral load <50 copies/mL at week 48, in an intention-to-treat analysis. Cost of initiating treatment with an ART regimen was defined as the costs of ART and its consequences (adverse effects, changes of ART regimen, and drug resistance studies) during the first 48 weeks. The payer perspective (National Health System) was applied considering only differential direct costs: ART (official prices), management of adverse effects, studies of resistance, and HLA B*5701 testing. The setting is Spain and the costs correspond to those of 2016. A sensitivity deterministic analysis was conducted, building three scenarios for each regimen: base case, most favourable and least favourable. Results: In the base case scenario, the cost of initiating treatment ranges from 4,663 Euros for 3TC + LPV/r (OR) to 10,894 Euros for TDF/FTC + RAL (PR). The efficacy varies from 0.66 for ABC/3TC + ATV/r (AR) and ABC/3TC + LPV/r (OR), to 0.89 for TDF/FTC + DTG (PR) and TDF/FTC/EVG/COBI (AR). The efficiency, in terms of cost/efficacy, ranges from 5,280 to 12,836 Euros per responder at 48 weeks, for 3TC + LPV/r (OR) and RAL + DRV/r (OR) respectively. Conclusion: Despite the overall most efficient regimen was 3TC + LPV/r (OR), among the PR and AR, the most efficient regimen was ABC/3TC/ DTG (PR). Among the AR regimes, the most efficient was TDF/FTC/RPV.
URI
http://hdl.handle.net/10459.1/70769
DOI
https://doi.org/10.1016/j.eimc.2016.06.013
Is part of
Enfermedades Infecciosas y Microbiología Clínica, 2017, vol. 35, núm. 2, p. 88-99
Collections

The following license files are associated with this item:

cc-by-nc-nd (c) Elsevier, 2017
Except where otherwise noted, this item's license is described as cc-by-nc-nd (c) Elsevier, 2017